Dana-Farber
AI tools have impressive potential in personalizing treatments, but doctors are concerned about bias, generalizability, and the lack of prospective validation.
The NEMO assay detects aggressive neuroendocrine prostate cancer early in its evolution, potentially enabling treatment before resistance arises.
Precede Biosciences Debuts Chromatin-Based Liquid Biopsy Platform Backed by New Data at ESMO
Premium
The firm has begun working with pharma, using its technology to identify and monitor transcriptionally regulated drug targets. It is also eyeing multiple clinical diagnostic applications.
Liquid Biopsy Company Precede Biosciences Emerges From Stealth With $57M in Financing
The firm's technology detects genome-wide patterns of gene activation, promotion, and methylation in circulating chromatin from a 1-mL plasma sample.
The innovative design enables the within-trial addition and removal of unpromising treatment arms and a shared, common comparator control arm.